Medications for Opioid Use Disorder Save Lives

Mancher, Michelle; Leshner, Alan I.

doi:10.17226/25310

Cited by 176 publications

(97 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Methadone was not included because it is solely dispensed from an opioid treatment program for patients with OUD. 9 Keywords were chosen based on the study authors' experiences in this topic area, and based on what they felt would garner appropriate literature for this publication. Articles that were identified as "related" or "citing" by the databases were also screened for relevance.…”

Section: Methodsmentioning

confidence: 99%

“…7,8 Increasing access to medication-based treatment are needed, as 1.4 million, or 80% of those diagnosed with an OUD, have not received an evidence-based treatment (such as methadone, buprenorphine, or naltrexone). 9 A majority of counties in the United States still lack waivered providers of buprenorphine, with rural populations still facing OUD treatment access disparities. 10 Approximately 30% of rural Americans, as compared with 2% of urban Americans, lack access to outpatient buprenorphine prescribers.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacists and the opioid crisis: A narrative review of pharmacists' practice roles

Bratberg

Smothers

Collins

et al. 2019

J Am Coll Clin Pharm

View full text Add to dashboard Cite

Introduction Nearly 2.5 million Americans have an opioid use disorder (OUD) related to prescription and/or illicit opioids. Pharmacists, as one of the most accessible care providers, are essential in mitigating the mortality and morbidity of the opioid overdose crisis. Pharmacists are involved in numerous care activities related to this crisis and to caring for patients with an OUD. Objective The objective of this paper was to conduct a literature review to highlight several pharmacist‐driven practices that provide a broad range of prevention, harm reduction, treatment, and recovery services to patients affected or potentially affected by the opioid crisis. Methods Articles had to meet the criteria of describing pharmacist‐led practice related to providing care to patients at risk of an opioid overdose, with an OUD, or related to opioid safety. The literature search was conducted in 2018 and utilized numerous sources including: OneSearch (EBSCOhost), PubMed, ScienceDirect, and the Journal of the American Pharmacists Association Opioid Topic Collection. Results Seven articles were chosen for inclusion in this review. These studies report on innovative programs and practices that describe the role of pharmacists in the opioid crisis. Studies demonstrate the types of involvement pharmacists have in caring for patients throughout the care continuum: actively engaged in upstream interventions aimed at preventing misuse and improve safety; screening and monitoring opioid prescribing and usage; providing access to naloxone; and, assisting in the recovery and rehabilitation process of patients with OUD, including collaboratively managing OUD with evidence‐based pharmacotherapy. Conclusion The studies included in our narrative review demonstrate how innovative programs and practices can expand the role of pharmacists throughout the entire spectrum of interventions applied to the opioid crisis by capitalizing on their existing skill sets and knowledge.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Pharmacists and the opioid crisis: A narrative review of pharmacists' practice roles

Bratberg

Smothers

Collins

et al. 2019

J Am Coll Clin Pharm

View full text Add to dashboard Cite

show abstract

“…11,12 In 2019, the National Academy of Sciences published a comprehensive report ("Medications for Opioid Use Disorder Save Lives") that explored the evidence base on MAT for OUD. 13 Multiple studies have validated the efficacy of buprenorphine treatment in adolescents and shown its superiority over abstinence-based treatment programs, 8e10 although there are only 3 randomized controlled trials that have generated data using buprenorphine and buprenorphine/naloxone to treat adolescents and young adults with OUD. 9,10,14 In 2016, the American Academy of Pediatrics published a policy statement endorsing the use (and research) of MAT for opioid addiction among adolescents and young adults and noted oral buprenorphine as the preferred medication.…”

Section: Introductionmentioning

confidence: 99%

Personal and Socioeconomic Determinants in Medication-assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults

Grubb

2019

Clinical Therapeutics

View full text Add to dashboard Cite

Opioid use disorder (OUD) is a pediatric and adolescent problem as most young adults (aged <25 years) in treatment programs report initiating use before 25 years of age, and there are lifelong impacts from early substance use necessitating early screening for opioid use and subsequent treatment. Medicationassisted treatment (MAT) is a highly effective intervention for OUD, and there is strong evidence for its use with adolescents; however, most adolescents with OUD are unable to access MAT or remain in MAT long term to achieve substantial recovery. Using case examples drawn from a pediatric and adolescent physician's experiences proving MAT to adolescents and young adults (ages 16e24 years), this article explores the personal and socioeconomic determinants in MAT of OUD in adolescents and young adults and provides suggestions for advocacy areas and resources to improve MAT with this population. (Clin Ther. 2019;41:1669e1680)

show abstract

“…Treatment systems need to facilitate uninterrupted access to the most effective medications for OUD treatment: methadone and buprenorphine (2). Regarding methadone, federal agencies relaxed requirements for physical examinations and allowed extended medication supply for stable patients (3).…”

mentioning

confidence: 99%

When Epidemics Collide: Coronavirus Disease 2019 (COVID-19) and the Opioid Crisis

Becker

Fiellin

2020

Annals of Internal Medicine

206

195

View full text Add to dashboard Cite

Medications for Opioid Use Disorder Save Lives

Cited by 176 publications

References 0 publications

Pharmacists and the opioid crisis: A narrative review of pharmacists' practice roles

Pharmacists and the opioid crisis: A narrative review of pharmacists' practice roles

Personal and Socioeconomic Determinants in Medication-assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults

When Epidemics Collide: Coronavirus Disease 2019 (COVID-19) and the Opioid Crisis

Contact Info

Product

Resources

About